ABOUT PEMBROLIZUMAB PATENT EXPIRY

Clinically sizeable immune-mediated hematologic adverse reactions (which includes hemolytic anemia, aplastic anemia, immune thrombocytopenic purpura) transpired at an incidence of fewer than 1% in patients who received this drug or had been documented with using other PD-one/PD-L1 blocking antibodies.In the event you have thoughts about what to exp